This company has been marked as potentially delisted and may not be actively trading. Presbia (LENS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock LENS vs. BVS, CATX, INFU, NSPR, CTCX, TMDIF, HSAQ, GBS, PETV, and RVPShould you be buying Presbia stock or one of its competitors? The main competitors of Presbia include Bioventus (BVS), Perspective Therapeutics (CATX), InfuSystem (INFU), InspireMD (NSPR), Carmell (CTCX), Titan Medical (TMDIF), Health Sciences Acquisitions Co. 2 (HSAQ), GBS (GBS), PetVivo (PETV), and Retractable Technologies (RVP). These companies are all part of the "medical" sector. Presbia vs. Its Competitors Bioventus Perspective Therapeutics InfuSystem InspireMD Carmell Titan Medical Health Sciences Acquisitions Co. 2 GBS PetVivo Retractable Technologies Bioventus (NYSE:BVS) and Presbia (NASDAQ:LENS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment. Do institutionals & insiders believe in BVS or LENS? 62.9% of Bioventus shares are owned by institutional investors. Comparatively, 16.4% of Presbia shares are owned by institutional investors. 33.0% of Bioventus shares are owned by insiders. Comparatively, 74.2% of Presbia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk & volatility, BVS or LENS? Bioventus has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Presbia has a beta of 2.57, suggesting that its share price is 157% more volatile than the S&P 500. Which has stronger earnings and valuation, BVS or LENS? Presbia has lower revenue, but higher earnings than Bioventus. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioventus$567.70M0.95-$156.23M-$0.48-13.69Presbia$20K24,395.96-$8.41MN/AN/A Is BVS or LENS more profitable? Bioventus has a net margin of -7.11% compared to Presbia's net margin of -36,604.35%. Bioventus' return on equity of 15.61% beat Presbia's return on equity.Company Net Margins Return on Equity Return on Assets Bioventus-7.11% 15.61% 4.01% Presbia -36,604.35%-414.02%-195.56% Does the media prefer BVS or LENS? In the previous week, Bioventus had 1 more articles in the media than Presbia. MarketBeat recorded 1 mentions for Bioventus and 0 mentions for Presbia. Bioventus' average media sentiment score of 1.68 beat Presbia's score of 0.00 indicating that Bioventus is being referred to more favorably in the media. Company Overall Sentiment Bioventus Very Positive Presbia Neutral Do analysts recommend BVS or LENS? Bioventus currently has a consensus price target of $13.75, indicating a potential upside of 109.28%. Given Bioventus' stronger consensus rating and higher probable upside, research analysts clearly believe Bioventus is more favorable than Presbia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bioventus 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Presbia 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryBioventus beats Presbia on 10 of the 14 factors compared between the two stocks. Get Presbia News Delivered to You Automatically Sign up to receive the latest news and ratings for LENS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LENS vs. The Competition Export to ExcelMetricPresbiaSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$487.92M$69.61M$5.70B$9.50BDividend YieldN/AN/A4.58%4.00%P/E RatioN/A6.5528.3920.08Price / Sales24,395.96148.79430.4988.77Price / CashN/A18.4136.2258.56Price / Book314.648.188.675.88Net Income-$8.41M-$25.92M$3.25B$258.89M Presbia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LENSPresbiaN/A$28.32-0.7%N/AN/A$487.92M$20K0.0024BVSBioventus3.3583 of 5 stars$6.44+2.2%$13.75+113.5%-11.8%$529.01M$567.70M-10.561,200CATXPerspective Therapeutics2.181 of 5 stars$4.30-0.2%$12.56+192.0%-70.2%$319.18MN/A0.0070News CoverageINFUInfuSystem3.3029 of 5 stars$5.75+4.4%$12.50+117.4%-12.9%$120.84M$137.58M95.85410News CoverageAnalyst ForecastAnalyst RevisionNSPRInspireMD2.5325 of 5 stars$2.51-0.4%$4.50+79.3%-18.5%$76.89M$7.03M-3.3550CTCXCarmellN/A$3.63-16.0%N/A+306.0%$75.89M$32.84K0.0014TMDIFTitan MedicalN/A$0.38+2.8%N/A+926.0%$43.37M$17.63M-0.3050HSAQHealth Sciences Acquisitions Co. 2N/A$3.16+2.3%N/A-60.0%$35.43MN/A0.004GBSGBSN/A$2.15+0.5%N/A+28.4%$32.01MN/A-3.847Gap UpPETVPetVivoN/A$0.84+0.6%N/A+23.1%$20.41M$1.05M-1.8620RVPRetractable Technologies1.9675 of 5 stars$0.67+0.8%N/A-39.6%$20.06M$33.75M-1.24240 Related Companies and Tools Related Companies BVS Competitors CATX Competitors INFU Competitors NSPR Competitors CTCX Competitors TMDIF Competitors HSAQ Competitors GBS Competitors PETV Competitors RVP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LENS) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Presbia PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Presbia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
